Last reviewed · How we verify
liraglutide combined with orlistat
Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption.
Liraglutide stimulates GLP-1 receptors to increase insulin secretion and reduce appetite, while orlistat inhibits pancreatic lipase to reduce dietary fat absorption. Used for Obesity and weight management, Type 2 diabetes mellitus with obesity.
At a glance
| Generic name | liraglutide combined with orlistat |
|---|---|
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Drug class | GLP-1 receptor agonist combined with pancreatic lipase inhibitor |
| Target | GLP-1 receptor (liraglutide); pancreatic and gastric lipases (orlistat) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Obesity |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a GLP-1 receptor agonist that enhances postprandial insulin secretion, slows gastric emptying, and promotes satiety through central nervous system effects. Orlistat is a lipase inhibitor that blocks the absorption of approximately 25-30% of dietary fat in the gastrointestinal tract. The combination targets weight loss through complementary mechanisms: appetite suppression and metabolic enhancement via liraglutide, and reduced caloric intake via orlistat.
Approved indications
- Obesity and weight management
- Type 2 diabetes mellitus with obesity
Common side effects
- Nausea
- Gastrointestinal disturbances (diarrhea, steatorrhea)
- Vomiting
- Abdominal pain
- Headache
- Hypoglycemia (if used with other antidiabetic agents)
Key clinical trials
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease (PHASE4)
- Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: